NCT06509243View on ClinicalTrials.gov

Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis

NACompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

April 10, 2024

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

tablets Acarizax

sublingual immunotherapy to house dust mites

BIOLOGICAL

dupilumab

dupilumab - biologic therapy for atopic dermatitis

DRUG

cyclosporine

cyclosporine used in atopic dermatitis

Trial Locations (1)

Unknown

SUM, Zabrze

All Listed Sponsors
lead

Medical University of Silesia

OTHER